by Site Strategics | Oct 14, 2021 | News
Several studies have recently been published, evaluated the MVista® CE marked Histoplasma urine antigen lateral flow immunoassay. The first study was conducted in Columbia in partnership with the CDC and reported high sensitivity with the MVD LFA. Read more about the...
by Site Strategics | Mar 3, 2021 | News
In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure...
by Site Strategics | Nov 30, 2020 | News
In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our referral testing customers. Beginning March 1, 2021 MiraVista Diagnostics will transition to an improved MVista® Histoplasma Antigen Quantitative...
by Site Strategics | May 14, 2020 | News
Are You Underdiagnosing Coccidioidomycosis? Capture Additional Cases with Combined Antigen and Antibody Testing. Dear Colleagues, The prevailing method for diagnosis of coccidioidomycosis is serum antibody testing by immunodiffusion (ID) with a sensitivity of 84.2%...
by Site Strategics | May 6, 2020 | News
In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our test report format to our referral testing customers. Minor changes have been made to the layout, while critical information such as test code,...
by Site Strategics | Mar 18, 2020 | News
MiraVista is open and continues to provide critical diagnostic testing despite the impact COVID-19 has had on staffing. The health and welfare of our team is of critical importance. To limit the opportunity of exposure to COVID-19 for our entire team, MiraVista will...